Please login to the form below

Not currently logged in
Email:
Password:

Akinion appoints Dr Richard Jones as CEO

He joins the biotech firm from GlaxoSmithKline

Akinion Dr Richard JonesDr Richard Jones has been appointed as chief executive officer for privately-held Swedish biotech firm Akinion Pharmaceuticals.

He brings more than 20 years of pharmaceutical industry experience to the company and arrives from Novartis where he was vice president, medicines commercialisation leader, haematology, global oncology.

Before that Dr Jones served at GlaxoSmithKline, where he was most recently VP, global haematology medicines commercialisation leader.

In that role he was responsible for delivering the big pharma company's global haematology strategy, and prior to he served at Sanofi Genzyme as director and M&A transition lead for its transplant and oncology global business unit.

In his new role at Akinion Pharmaceuticals Dr Jones will oversee a company focused on acute myeloid leukaemia and its lead candidate drug AKN-028, a small molecule kinase inhibitor currently in a phase I/II clinical trial.

27th January 2016

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Spirit

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...
wearable health tech
A cultural shift in clinical research
Research organisations across the board are experimenting with new technologies...

Infographics